Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 5/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3026875 | 1.00 | F12 (0.37) | F12POLBAGTR1KIF11NUDT1 | |
| SCHEMBL4361369 | 1.00 | F12 (0.37) | F12POLBAGTR1KIF11NUDT1 | |
| SCHEMBL3020886 | 0.85 | GRIA1 (0.33) | F12POLBALDH1A1 | |
| SCHEMBL3020889 | 0.85 | GRIA1 (0.33) | F12POLBALDH1A1 | |
| SCHEMBL3028481 | 0.84 | CHRM2 (0.37) | — | |
| SCHEMBL14311499 | 0.84 | CHRM2 (0.37) | — | |
| SCHEMBL3028483 | 0.84 | CHRM2 (0.37) | — | |
| SCHEMBL4349102 | 0.84 | PARP1 (0.40) | ALDH1A1PARP1 | |
| SCHEMBL3020890 | 0.84 | PARP1 (0.40) | ALDH1A1PARP1 | |
| SCHEMBL3020895 | 0.84 | PARP1 (0.40) | ALDH1A1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | claimed |
| EP-1957486-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PainCeptor Pharma Corp. (CA) | 2008-08-20 | — | — | EP | claimed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | claimed |
| WO-2007059608-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | WO | claimed |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | AROS PHARMA APS (DK) | 2010-08-05 | — | — | US | disclosed |
| US-7718641-B2 | Pyrrolo [3,4-H] isoquinoline compounds and methods for modulating gated ion channels | AROS PHARMA APS (DE) | 2010-05-18 | — | — | US | disclosed |
| EP-1957486-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PainCeptor Pharma Corp. (CA) | 2008-08-20 | — | — | EP | disclosed |
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | AROS PHARMA APS (DK) | 2007-08-16 | — | — | US | disclosed |
| WO-2007059608-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191418-A1 | Compositions and methods for modulating gated ion channels | KCNN3, KCNN2, HCN3 | F12 4561/4885POLB 4232/4885AGTR1 3512/4885 |
| US-20100197721-A1 | PYRROLO [3, 4-h] ISOQUINOLINE COMPOUNDS AND METHODS FOR MODULATING GATED ION CHANNELS | KCNQ1, KCNQ2, KCNH3 | F12 4878/4885POLB 3390/4885AGTR1 3129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.